Stifel initiated coverage on Rapport Therapeutics with a new price target
$RAPP
Biotechnology: Pharmaceutical Preparations
Health Care
Stifel initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2025 | Mkt Outperform | Citizens JMP | |
| 7/2/2024 | Buy | TD Cowen | |
| 7/2/2024 | $35.00 | Buy | Jefferies |
| 7/2/2024 | $35.00 | Buy | Stifel |
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in three upcoming investor conferences. Jones Trading Virtual CNS Symposium - fireside chat on Tuesday, April 29, 2025, from 11:00-11:25am ET. Citizens JMP 2025 Life Sciences Conference (New York City) - fireside chat on Thursday, May 8, 2025, from 1:30-1:55pm ET. Mizuho Neuro & Ophthalmology Summit 2025 (New York City) - investor meet
BOSTON and SAN DIEGO, March 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society (AES) Annual Meeting in December 2024. The presentations will highlight the company's ongoing research and development of RA
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027 Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer Ended the year with $305.3 million in cash, cash equivalents, an
Citizens JMP initiated coverage of Rapport Therapeutics with a rating of Mkt Outperform
TD Cowen initiated coverage of Rapport Therapeutics with a rating of Buy
Jefferies initiated coverage of Rapport Therapeutics with a rating of Buy and set a new price target of $35.00
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G/A - Rapport Therapeutics, Inc. (0002012593) (Subject)
SC 13G - Rapport Therapeutics, Inc. (0002012593) (Subject)
DEFA14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
DEF 14A - Rapport Therapeutics, Inc. (0002012593) (Filer)
S-8 - Rapport Therapeutics, Inc. (0002012593) (Filer)
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS) disorders Continued momentum in the Phase 2a trial of RAP-219 in patients with refractory focal epilepsy, with topline results expected in the third quarter of 2025Expect to initiate a Phase 2a trial in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027 Appointed recognized translational and clinical drug development leader, Jeffrey Sevigny, M.D., as chief medical officer Ended the year with $305.3 million in cash, cash equivalents, an
BOSTON and SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced the appointment of Dr. Jeffrey Sevigny as chief medical officer (CMO), effective immediately. A physician-scientist with more than 15 years of leadership in translational and clinical drug development, Dr. Sevigny has spearheaded groundbreaking research across neuroscience and rare diseases. His experience spans the full spectrum of development, from discovery to late-stage clinical trials an
Biotech industry leaders added to the Board of Directors, bringing deep expertise in drug discovery, neuroscience clinical development, and operational leadershipRAP-219 MAD-2 and PET trials ongoing; topline data expected in Q1 2025Actively recruiting patients for Phase 2a trial of RAP-219 in focal epilepsy; trial on track and topline data expected in mid-2025 Investigational New Drug Application (IND) in diabetic peripheral neuropathic pain placed on clinical hold while the Company addresses U.S. Food and Drug Administration (FDA) Phase 2a trial protocol feedback Ended the quarter with $320.7 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is